Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.

(2017) Reza Khosravan et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes

(2017) Gary H. Lyman   Journal of the National Comprehensive Cancer Network

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

(2016) Michael J Sorich et al.   BRITISH JOURNAL OF CANCER

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours

(2016) Andrew Rowland et al.   EUROPEAN JOURNAL OF CANCER

Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia

(2016) Gloria Ravegnini et al.   Expert Opinion on Drug Metabolism & Toxicology

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non–Small-Cell Lung Cancer

(2016) Roelof W.F. van Leeuwen et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer

(2016) Andrew Rowland et al.   Translational Cancer Research

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

(2015) Andrew Rowland et al.   BRITISH JOURNAL OF CANCER

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

(2015) A Rowland et al.   BRITISH JOURNAL OF CANCER

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

(2015) Jan de Jong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

(2015) A. Nair et al.   CLINICAL CANCER RESEARCH

Individualized dosing of tyrosine kinase inhibitors: are we there yet?

(2015) Djoeke de Wit et al.   DRUG DISCOVERY TODAY

The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

(2015) Feng Jin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

(2015) Yvonne Y. Lau et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

(2015) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Impact ofCYP2C8*3polymorphism onin vitrometabolism of imatinib to N-desmethyl imatinib

(2015) Muhammad Suleman Khan et al.   XENOBIOTICA

Oral Anticancer Medication Adherence, Toxicity Reporting, and Counseling: A Study Comparing Health Care Providers and Patients

(2015) Sonal Gandhi et al.   Journal of Oncology Practice

ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials

(2014) M. J. Sorich et al.   ANNALS OF ONCOLOGY

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

(2014) N A G Lankheet et al.   BRITISH JOURNAL OF CANCER

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

(2014) A B Suttle et al.   BRITISH JOURNAL OF CANCER

Pharmacokinetics of pazopanib administered in combination with bevacizumab

(2014) Diane-Charlotte Imbs et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects

(2014) Narayana I. Narasimhan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetics of single-agent axitinib across multiple solid tumor types

(2014) Michael A. Tortorici et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

(2014) G. S. Falchook et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

(2014) G. Kim et al.   CLINICAL CANCER RESEARCH

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

(2014) Huixin Yu et al.   CLINICAL PHARMACOKINETICS

A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

(2014) Y.G. Najjar et al.   EUROPEAN JOURNAL OF CANCER

Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions

(2014) Ben D. Snyder et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective

(2014) Niels Eckstein et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors

(2014) Jie Shao et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

(2014) Roelof W F van Leeuwen et al.   LANCET ONCOLOGY

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

(2013) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacology of Axitinib

(2013) Ying Chen et al.   CLINICAL PHARMACOKINETICS

Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma

(2013) Masahide Fukudo et al.   CLINICAL PHARMACOKINETICS

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study

(2013) Jacqueline S. L. Kloth et al.   CLINICAL PHARMACOKINETICS

Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects

(2013) M Ulvestad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

(2013) K-H Shin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors

(2013) C D Drenberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

(2013) Devron R. Shah et al.   DRUG SAFETY

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study

(2013) Jordi Bruix et al.   EUROPEAN JOURNAL OF CANCER

Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs

(2013) Ichiro Ieiri et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

(2013) Brian I. Rini et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

(2013) Marcello Tiseo et al.   LUNG CANCER

Modulation of OATP1B-Type Transporter Function Alters Cellular Uptake and Disposition of Platinum Chemotherapeutics

(2013) C. S. Lancaster et al.   MOLECULAR CANCER THERAPEUTICS

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature

(2013) Georg A. Bjarnason et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer

(2013) Yanli Deng et al.   XENOBIOTICA

A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction

(2012) Yvonne Mårde Arrhén et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

(2012) A.-J. M. de Graan et al.   CLINICAL CANCER RESEARCH

Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib

(2012) Julia Clemons et al.   Clinical Genitourinary Cancer

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma

(2012) M. Daimon et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies

(2012) Bo Gao et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials

(2012) Fausto Petrelli et al.   LUNG CANCER

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

(2012) Laure Elens et al.   PHARMACOGENOMICS

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

(2012) M. McTigue et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

(2011) A C Mita et al.   BRITISH JOURNAL OF CANCER

Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment

(2011) Thomas M. Polasek et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

(2011) Peter Stopfer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

(2011) T. Yau et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Matthias Scheffler et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Paola Di Gion et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects

(2011) Paul Martin et al.   CLINICAL THERAPEUTICS

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

(2011) Richard A. Larson et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer

(2011) R. W. Humphrey et al.   JNCI-Journal of the National Cancer Institute

Polypharmacy in elderly patients with cancer: clinical implications and management

(2011) Judith Lees et al.   LANCET ONCOLOGY

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

(2011) Sai-Hong Ignatius Ou   Drug Design Development and Therapy

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

(2010) Fabio P. S. Santos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Moving towards dose individualization of tyrosine kinase inhibitors

(2010) Heinz-Josef Klümpen et al.   CANCER TREATMENT REVIEWS

Food and Oral Antineoplastics: More Than Meets the Eye

(2010) R. K. Jain et al.   CLINICAL CANCER RESEARCH

The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib

(2010) Yuan-Yuan Zhao et al.   MEDICAL ONCOLOGY

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

(2010) B. Vincenzi et al.   ONCOLOGIST

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib

(2010) L. M. Riesenbeck et al.   WORLD JOURNAL OF UROLOGY

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

(2009) Jie Ling et al.   ANTI-CANCER DRUGS

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

(2008) N Widmer et al.   BRITISH JOURNAL OF CANCER

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

(2008) M. Hazarika et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer

(2008) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE